Hot on the heels of approval by the US Food and Drug Administration (FDA), Sarepta has announced the price of its Elevidys, its new gene therapy for Duchenne muscular dystrophy, at $3.2 million. This makes it one of the most expensive therapeutics in history. However, Sarepta claims this price is far below it’s initial cost-effectiveness estimates.
According to Ben Fidler, “On a conference call following the FDA’s decision, Sarepta CEO Doug Ingram said the price reflected a ‘conservative’ approach to valuing the benefit to patients and their families of Elevidys, which Sarepta claims would be cost-effective at prices between $5 million and $13 million.”
To read more, click here.
(Source: Biopharma Dive, June 22nd, 2023)